Principal Financial Group Inc. Reduces Holdings in Pfizer Inc. $PFE

Principal Financial Group Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 0.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,137,760 shares of the biopharmaceutical company’s stock after selling 52,625 shares during the period. Principal Financial Group Inc. owned 0.11% of Pfizer worth $156,390,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PFE. Curio Wealth LLC grew its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the third quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer in the second quarter valued at approximately $30,000. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Bank of America cut their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Morgan Stanley cut their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a report on Friday, December 12th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Stock Up 0.9%

Shares of NYSE:PFE opened at $26.68 on Tuesday. The firm’s 50-day moving average is $25.54 and its two-hundred day moving average is $25.05. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a market capitalization of $151.67 billion, a PE ratio of 15.51 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $27, citing a shifting focus on obesity data that could re-rate Pfizer if pipeline results improve. Cantor Fitzgerald Raises PT to $27
• Positive Sentiment: UK industry self-regulator found Sanofi breached rules with unsubstantiated claims about its RSV therapy versus Pfizer’s vaccine — a reputational win that supports Pfizer’s vaccine positioning. Sanofi Breach Over RSV Claims
• Positive Sentiment: Management is reshaping the portfolio toward obesity, vaccines and pricing changes; investors see this as a potential multi-year growth pivot and yield support (Pfizer is highlighted for income investors). Pfizer Reshapes Portfolio With Obesity Bet
• Neutral Sentiment: Q4 earnings are due Feb. 3 before the open; previews focus attention on pipeline commentary (especially obesity/GLP-1 positioning) and guidance — the release, not yet reflected in results, is the main near-term catalyst. Is Pfizer a Good Stock to Buy before Earnings?
• Negative Sentiment: Several outlets and analyst models expect lower Q4 earnings and some firms have trimmed forecasts ahead of the call — downside surprise to EPS or guidance could pressure the stock. Pfizer Likely To Report Lower Q4 Earnings
• Negative Sentiment: Ongoing structural headwinds — patent expiries on blockbusters, intense GLP‑1 competition and pricing pressure — remain material risks that could limit upside absent strong pipeline news. 3 Headwinds Facing Pfizer in 2026

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.